Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

Cancer

Volumn 122, Issue 19, 2016, Pages 3051-3058

  Qian, Jack M ^a   Yu, James B ^a   Kluger, Harriet M ^a   Chiang, Veronica L S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti cytotoxic T lymphocyte associated protein 4 (anti CTLA 4); Anti programmed cell death protein 1 (anti PD 1); Brain metastases; Immunotherapy; Melanoma; Stereotactic radiosurgery

Indexed keywords

B RAF KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LESION VOLUME; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CANCER STAGING; CELL CYCLE CHECKPOINT; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIOSURGERY; SECONDARY; SURVIVAL RATE; TIME TO TREATMENT;

BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIOSURGERY; RETROSPECTIVE STUDIES; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TIME-TO-TREATMENT;

EID: 84994137730     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30138     Document Type: Article

References (21)

1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48-54.
2. Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol. 2014;16:276.
3. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010;120:1368-1379.
4. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459-465.
5. Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2:210-225.
6. Order SE. The effects of therapeutic irradiation on lymphocytes and immunity. Cancer. 1977;39:737-743.
7. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498-e509.
8. Kreamer KM. Immune checkpoint blockade: a new paradigm in treating advanced cancer. J Adv Pract Oncol. 2014;5:418-431.
9. Wargo JA, Reuben A, Cooper ZA, Oh KS, Sullivan RJ. Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy. Semin Oncol. 2015; 42:601-616.
10. Ramakrishna N, Margolin KA. Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am Soc Clin Oncol Educ Book. 2013:399-403.
11. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47:291-298.
12. Patel TR, McHugh BJ, Bi WL, Minja FJ, Knisely JP, Chiang VL. A comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases. AJNR Am J Neuroradiol. 2011;32:1885-1892.
13. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117:227-233.
14. Patel KR, Shoukat S, Oliver DE, et al. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol. 2015. [Epub ahead of print].
15. Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti– PD-1 therapy. Ann Oncol. 2016;27:434-441.
16. Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92:368-375.
17. Schoenfeld JD, Mahadevan A, Floyd SR, et al. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015;3:50.
18. Jiang W, Rodriguez Y, Kim BYS, et al. Temporally-dependent intracranial control of melanoma brain metastasis by stereotactic radiation therapy in patients treated with immune checkpoint blockade. Int J Radiat Oncol Biol Phys. 2015;93:S57.
19. Sharpton SR, Oermann EK, Moore DT, et al. The volumetric response of brain metastases after stereotactic radiosurgery and its post-treatment implications. Neurosurgery. 2014;74:9-15.
20. Kim WH, Kim DG, Han JH, et al. Early significant tumor volume reduction after radiosurgery in brain metastases from renal cell carcinoma results in long-term survival. Int J Radiat Oncol Biol Phys. 2012;82:1749-1755.
21. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.